Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 May 2008, Vol. 111, No. 9, pp. 4731-4740.
Prepublished online as a Blood First Edition Paper on January 16, 2008; DOI 10.1182/blood-2007-09-110544.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-09-110544v1
111/9/4731    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Di Bartolo, D. L.
Right arrow Articles by Cesarman, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Bartolo, D. L.
Right arrow Articles by Cesarman, E.
Related Collections
Right arrow Neoplasia
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

KSHV LANA inhibits TGF-β signaling through epigenetic silencing of the TGF-β type II receptor

Daniel L. Di Bartolo1, Mark Cannon2, Yi-Fang Liu1, Rolf Renne3, Amy Chadburn1, Chris Boshoff2, and Ethel Cesarman1

1 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY; 2 Cancer Research UK Viral Oncology Group, Wolfson Institute for Biomedical Research, University College London, London, United Kingdom; and 3 University of Florida, Shands Cancer Center, Gainesville

Signaling through the transforming growth factor–β (TGF-β) pathway results in growth inhibition and induction of apoptosis in various cell types. We show that this pathway is blocked in Kaposi sarcoma herpesvirus (KSHV)–infected primary effusion lymphoma through down-regulation of the TGF-β type II receptor (TβRII) by epigenetic mechanisms. Our data also suggest that KSHV infection may result in lower expression of TβRII in Kaposi sarcoma and multicentric Castleman disease. KSHV-encoded LANA associates with the promoter of TβRII and leads to its methylation and to the deacetylation of proximal histones. Reestablishment of signaling through this pathway reduces viability of these cells, inferring that KSHV-mediated blockage of TGF-β signaling plays a role in the establishment and progression of KSHV-associated neoplasia. These data suggest a mechanism whereby KSHV evades both the antiproliferative effects of TGF-β signaling by silencing TβRII gene expression and immune recognition by suppressing TGF-β–responsive immune cells through the elevated secretion of TGF-β1.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

KSHV LANA's expanding bag of tricks
Andrew J. Barbera and Kenneth M. Kaye
Blood 2008 111: 4425-4426. [Full Text] [PDF]





click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020